Amgen wins ruling on arthritis drug royalties
- Share via
Amgen Inc. won an appeals court ruling that prevents an Israeli company from seeking royalties on Enbrel, a rheumatoid arthritis treatment.
Israel Bio-Engineering Project sued Thousand Oaks-based Amgen and its marketing partner Wyeth, claiming they infringed a U.S. patent that covers Enbrel.
The appeals court upheld a finding that Yeda Research and Development Co., which licenses inventions of the Weizmann Institute of Science in Israel, was at least a part owner of the patent, blocking a suit by Israel Bio-Engineering.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
